Modeling of the time-dependency of in vitro drug cytotoxicity and resistance

Cancer Research

Volumn 58, Issue 24, 1998, Pages 5749-5761

  Levasseur, Laurence M ^a   Slocum, Harry K ^a   Rustum, Youcef M ^a   Greco, William R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; METHOTREXATE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; PACLITAXEL; RALTITREXED; RHODAMINE B; TRIMETREXATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RESISTANCE; HUMAN; HUMAN CELL; MODEL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; MODELS, BIOLOGICAL; STATISTICS; TIME FACTORS;

EID: 0032534995     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gibaldi, M., and Perrier, D. Pharmacokinetics, Ed. 2, Vol. 15, pp. 445-449. New York: Marcel Dekker, 1982.
2. Belani, C. P., Kim, K., Bonomi, P., and Johnson, D. Retrospective estimation of carboplatin exposure by Calvert's and Chatelut's formulae and correlation with pharmacodynamic effects in metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: A1119, 1996.
3. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F., and Mathieu-Boue, A. Pharmacokinetics and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Natl Cancer Inst. (Bethesda), 14: 2688-2695, 1996.
4. Sasaki, Y., Hakusui, H., Mizuno, S., Morita, M., Miya, T., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., and Saijo, N. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn. J. Cancer Res., 86: 101-110, 1995.
5. Rushing, D. A., Raber, S. R., Rodvold, K. A., Piscitelli, S. C., Plank, G. S., and Tewksbury, D. A. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer (Phila.), 74: 834-841, 1994.
6. Robert, J., Monnier, A., Poutignat, N., and Herait, P. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Cancer Chemother. Pharmacol., 29: 75-79, 1991.
7. Evans, W. E. Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut, 56: 241-248, 1988.
8. Greco, W. R., and Hakala, M. T. Biochemical pharmacology of lipophilic diaminopyrimidine antifolates in mouse and human cells in vitro. Mol. Pharmacol., 18: 521-528, 1980.
9. Rupniak, H. T., Whelan, R. D., and Hill, B. T. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int. J. Cancer, 32: 7-12, 1983.
10. Adams, D. J. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res., 49: 6615-6620, 1989.
11. Kurihara, N., Kubota, T., Hoshiya, Y., Otani, Y., Watanabe, M., Kumai, K., and Kitajima, M. Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice. J. Surg. Oncol., 61: 138-142, 1996.
12. Kalns, J. E., Millenbaugh, N. J., Wientjes, M. G., and Au, J. L. Design and analysis of in vitro antitumor pharmacodynamic studies. Cancer Res., 55: 5315-5322, 1995.
13. Hill, A. V. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol., 40: iv-vii, 1910.
14. Holford, N. H., and Sheiner, L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet., 6: 429-453, 1981.
15. Waud, D. R., and Parker, R. B. Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. II. Competitive antagonists. J. Pharmacol. Exp. Ther., 177: 13-24, 1971.
16. Chick, H. An investigation of the laws of disinfection. J. Hyg., 8: 92-158, 1908.
17. Hill, B. T., and Whelan, R. D. Assessments of the sensitivities of cultured human neuroblastoma cells to anti-tumour drugs. Pediatr. Res., 15: 1117-1122, 1981.
18. Bruce, W. R., Meeker, B. E., and Valeriote, F. A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemomerapeutic agents administered in vivo. J. Natl Cancer Inst. (Bethesda), 37: 233-245, 1966.
19. Stewart, D. J., Raaphorst, G. P., Yau, J., and Beaubien, A. R. Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation. A hypothesis. Invest. New Drugs, 14: 115-130, 1996.